Leishmaniasis (Kala-Azar) R&D Pipeline Analysis Report, Q4 2020

Leishmaniasis (Kala-Azar) R&D Pipeline Analysis Report, Q4 2020

  • October 2020 •
  • 93 pages •
  • Report ID: 5978225 •
  • Format: PDF
Leishmaniasis (Kala-Azar) Pipeline Overview

The Q4 Leishmaniasis (Kala-Azar) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Leishmaniasis (Kala-Azar), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Leishmaniasis (Kala-Azar) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Leishmaniasis (Kala-Azar) disease overview, Leishmaniasis (Kala-Azar) types, Leishmaniasis (Kala-Azar) symptoms, causes, and FDA/EMA approved treatment options.

Leishmaniasis (Kala-Azar) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Leishmaniasis (Kala-Azar) indication. The report presents near-term and long-term pipeline development trends and potential insights.

Leishmaniasis (Kala-Azar) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 26 companies. Business profiles and contact details of the companies actively perusing Leishmaniasis (Kala-Azar) pipeline are assessed.

Leishmaniasis (Kala-Azar) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Leishmaniasis (Kala-Azar) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Leishmaniasis (Kala-Azar) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Leishmaniasis (Kala-Azar) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Leishmaniasis (Kala-Azar) Pipeline Market News and Developments during 2020
The Leishmaniasis (Kala-Azar) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Leishmaniasis (Kala-Azar) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage
• Leishmaniasis (Kala-Azar) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
• Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
• Company-company partnerships, company-institute partnerships, and investment details of companies are included
• 26 companies are included including Acea Biotech Inc, Anacor Pharmaceuticals, Biokawthar Technologies SAS, BioLingus AG, Daiichi Sankyo Co Ltd, DetectoGen Inc, GlaxoSmithKline Plc, iCo Therapeutics Inc., Immune Modulation Inc, Impetis Biosciences Ltd, Laboratorios LETI SL, ManRos Therapeutics, Matinas BioPharma, MedC Biopharma Ltd, Mind Medicine Inc, Molecular Targeting Technologies Inc, Mycosynthetix Inc, NanoCliq LLC, Nanomerics Ltd, Novartis AG, Oblita Therapeutics BVBA, Pai Life Sciences Inc, Pfizer Inc, Pharos I&BT Co Ltd, Rakta Therapeutics Inc, Synstar Japan Co Ltd,
• Disease overview, Pipeline trends, market analysis, and other developments
• Potential licensing/new business opportunities in Leishmaniasis (Kala-Azar) pipeline market

Highlights
• Global coverage of companies and pipeline agents
• 2020 Trends, market analysis, and developments
• Potential growth opportunities
• Comprehensive details of drug candidates

Reasons to Buy
• Drive pipeline research and commercial assessment
• Assess most promising drug candidates and stay ahead of the competition
• Strengthen your pipeline through identifying business expansion and acquisition opportunities
• Develop new candidates based on most focused targets and mechanism of actions